Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System

This study has been terminated.
(Data was inconclusive)
Information provided by (Responsible Party):
Vessix Vascular, Inc Identifier:
First received: April 13, 2009
Last updated: June 19, 2013
Last verified: June 2013

The objective of this clinical investigation is to evaluate the safety and efficacy of the Minnow Medical GRST™ Peripheral Catheter System in the treatment of de novo lesions in the superficial femoral artery (SFA) or the popliteal artery.

Condition Intervention Phase
Peripheral Vascular Disease
Device: GRST Peripheral Catheter System
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System

Resource links provided by NLM:

Further study details as provided by Vessix Vascular, Inc:

Primary Outcome Measures:
  • Major Adverse Clinical Events Rate [ Time Frame: Up to 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Binary Restenosis [ Time Frame: 30 days, 3 months, 6 months and 12 months ] [ Designated as safety issue: No ]
  • Target Lesion Revascularization [ Time Frame: 30 days, 3 months, 6 months and 12 months ] [ Designated as safety issue: No ]
  • Amputation Rate [ Time Frame: 30 days, 3 months, 6 months, and 12 months ] [ Designated as safety issue: No ]
  • Technical Success [ Time Frame: Treatment ] [ Designated as safety issue: No ]
  • Serious Adverse Events rate, including Major Adverse Clinical Events [ Time Frame: 30 days, 3 months, 6 months, and 12 months ] [ Designated as safety issue: Yes ]

Enrollment: 78
Study Start Date: August 2007
Study Completion Date: May 2010
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
GRST Peripheral Catheter System
Device: GRST Peripheral Catheter System
Treatment to dilate stenoses and reduce plaque in treated vessels


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is ≥18 of age.
  2. Patient is Rutherford category 2-4.
  3. De novo single lesion with a diameter stenosis (%DS) of ≥50%
  4. Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%.
  5. Target lesion stenosis has a length of ≤100 mm based on visual assessment.
  6. Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment.
  7. Angiographic evidence of distal runoff defined as minimum one patent tibial artery with a straight flow to the foot.
  8. Patient is willing and able to provide written informed consent prior to any study specific procedure.
  9. Patient is willing and able to comply with specified follow-up evaluations at the specified times.

Exclusion Criteria:

  1. Prior PTA in the intended target lesion including 10 mm proximal or distal from the intended treatment area.
  2. Evidence of thrombus in the target vessel.
  3. Prior ipsilateral or contralateral lower limb arterial bypass.
  4. Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure.
  5. Target lesion is severely calcified.
  6. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
  7. Any planned surgery within 30 days of the study procedure.
  8. Renal failure (serum creatinine > 2.0 mg/dL).
  9. Female with childbearing potential without a negative pregnancy test.
  10. Patient has had an organ transplant.
  11. Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study.
  12. In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00881257

Herz-Zentrum Bad Krozingen
Bad Krozingen, Germany, 79189
Hamburg University Cardiovascular Center
Hamburg, Germany, 22527
Sponsors and Collaborators
Vessix Vascular, Inc
Principal Investigator: Hans Krankenberg, MD Hamburg University Cardiovascular Center
  More Information

No publications provided

Responsible Party: Vessix Vascular, Inc Identifier: NCT00881257     History of Changes
Other Study ID Numbers: DR0148
Study First Received: April 13, 2009
Last Updated: June 19, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Vessix Vascular, Inc:
Peripheral Vascular Disease
Peripheral Artery Disease

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Cardiovascular Diseases processed this record on March 03, 2015